Lung Cancer

Homeopathic Add-On Improves QOL, Survival in Non-Small Cell Lung Cancer

By

Vicki Moore, PhD

Publish Date November 21, 2022

A 3-arm study sought to compare the effects of homeopathic treatments on quality of life with placebo, and survival time with placebo or no treatment.

FDA Approves Drug Combo for Metastatic Non-Small Cell Lung Cancer

Publish Date November 21, 2022

Approval is for tremelimumab in combination with durvalumab and platinum-based chemotherapy.

Aprepitant Better Than Desloratadine for EGFR-TKI Treatment-Induced Pruritus

By

Vicki Moore, PhD

Publish Date November 18, 2022

A prospective study compared aprepitant with desloratadine for the relief of treatment-induced pruritus in patients with lung cancer treated with EGFR-TKIs.

SABR ‘Quite Safe’ for Treating Oligometastases

By

John Schieszer, MA

Publish Date November 18, 2022

Investigators characterized the toxicity of stereotactic body radiotherapy for oligometastases from predominantly prostate, colorectal, breast, and lung cancer.

Sex-Associated Differences in Lung Cancer Risks, Prognosis, Nurses’ Role

By

Vicki Moore, PhD

Publish Date November 17, 2022

A review of lung cancer in men and women described the sex-associated differences in risks, prognosis, and care of patients with the disease.

Lung Cancer Clinical Trials

Clinical Trial: Protein and RNA Expression Patterns in Predicting Response to Treatment in Patients With Lung Cancer

Clinical Trial: Improving Management of Breathlessness in Patients With Lung Cancer

Clinical Trial: Lung Cancer Screening Study With Low-dose CT Scan and Blood Biomarker

Clinical Trial: Lung Cancer Biomarkers and Screening (NYULCBC)

Clinical Trial: Proton Therapy for Stage I Non-Small Cell Lung Cancer (LU03)